NCT02474680

Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 84 (actual)
• Sponsor: Avera McKennan Hospital & University Health Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants.

Detailed description

This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants. Retrospective and prospective data will be collected on all subjects before and after pharmacogenetic recommendations have been made. Retrospective data will be collected for the previous 12 months before pharmacogenetic recommendations are made and prospective data will be collected for 12 months after pharmacogenomic recommendations have been made.

Conditions

• Major Depressive Disorder 1

Interventions

Type	Name	Description
GENETIC	Pharmacogenetic testing	Psychotropic genotyping panel

Timeline

• Start date: 2015-11-01
• Primary completion: 2017-01-01
• Completion: 2017-01-01
• First posted: 2015-06-18
• Last updated: 2017-05-03

Locations

1 site across 1 country: United States